Form 4: Lemaitre Vascular Director John Roush Reports Accrual of Dividend Equivalent Rights

Lemaitre Vascular Inc. Director John A. Roush reported the accrual of additional dividend equivalent rights tied to his existing restricted stock unit and performance share unit awards.

Summary

• John A. Roush, a Director at Lemaitre Vascular Inc. (LMAT), reported changes in his beneficial ownership of derivative securities.
• On May 29, 2025, Mr. Roush acquired Dividend Equivalent Rights (DERs) related to previously granted equity awards.
• The acquired DERs include: 0.4985 units tied to a Restricted Stock Unit (RSU) award from December 12, 2022; 0.4985 units tied to a Performance Share Unit (PSU) award from December 12, 2022; 0.8524 units tied to an RSU award from December 8, 2023; 1.0208 units tied to a PSU award from December 8, 2023; and 1.0387 units tied to an RSU award from December 6, 2024.
• Each Dividend Equivalent Right is the economic equivalent of one share of Lemaitre Vascular's common stock and vests proportionately with its corresponding underlying RSU or PSU award.
• Following these transactions, Mr. Roush beneficially owns a total of 6.0983 DERs related to the 12/12/2022 RSU, 5.1096 DERs related to the 12/12/2022 PSU, 4.6837 DERs related to the 12/8/2023 RSU, 5.0145 DERs related to the 12/8/2023 PSU, and 2.0397 DERs related to the 12/6/2024 RSU.

Sentiment

Score: 5

Explanation: The document is a routine disclosure of an insider's accrual of dividend equivalent rights on existing equity awards. It does not contain information that would significantly alter the company's financial outlook or operational status, thus indicating a neutral sentiment.

Positives

• The accrual of Dividend Equivalent Rights aligns the director's financial interests with those of common shareholders, as these rights are tied to the performance and vesting of equity awards.
• This is a routine disclosure related to existing compensation plans, indicating ongoing adherence to corporate governance and transparency requirements.

Negatives

• No direct negatives are apparent from this routine insider transaction filing.

Risks

• No specific risks are detailed within this Form 4 filing.

Future Outlook

NA

Industry Context

This Form 4 filing is a routine disclosure of an insider's equity compensation accrual and does not provide broader industry context or trends. It pertains specifically to the compensation structure for a director at Lemaitre Vascular Inc.

Stakeholder Impact

• Shareholders: The accrual of dividend equivalent rights for a director aligns their interests with shareholders, as these rights are tied to the company's stock performance and dividend policy.
• Employees: No direct impact on general employees is indicated by this filing.

Next Steps

• Continued vesting of the underlying Restricted Stock Unit (RSU) and Performance Share Unit (PSU) awards, to which these dividend equivalent rights are tied.

Key Dates

Keywords

Lemaitre Vascular, LMAT, SEC Form 4, insider transaction, beneficial ownership, dividend equivalent rights, restricted stock units, performance share units, director compensation, equity awards